InsiderClue
Stocks · Health care · Pharmaceutical Preparations

BRIGHT MINDS BIOSCIENCES INC.

DRUG Clue Score33
United States Fiscal year ends September CIK 0001827401
$54.05 +3.94% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $54.05 +589.41% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 22 Mar 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Net income
Fiscal year 2019Fiscal year 2020Net income−0.5EPS, diluted−0.13Fiscal year 2021Net income−8.7EPS, diluted−4.82Fiscal year 2022Net income−15.0EPS, diluted−6.06Fiscal year 2023Net income−7.4EPS, diluted−1.98Fiscal year 2024Net income−2.8EPS, diluted−0.65
FY2019FY2020FY2021FY2022FY2023FY2024
Net income n/a −0.5 −8.7 −15.0 −7.4 −2.8
Growth
EPS, diluted n/a −0.13 −4.82 −6.06 −1.98 −0.65

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2019Fiscal year 2020Operating cash flow−0.3Fiscal year 2021Operating cash flow−7.3Fiscal year 2022Operating cash flow−13.6Fiscal year 2023Operating cash flow−7.0Fiscal year 2024Operating cash flow−1.9
FY2019FY2020FY2021FY2022FY2023FY2024
Operating cash flow n/a −0.3 −7.3 −13.6 −7.0 −1.9

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2019Cash0.1Shareholders’ equity0.0Fiscal year 2020Cash0.8Shareholders’ equity0.7Fiscal year 2021Cash19.8Shareholders’ equity19.4Fiscal year 2022Cash11.6Shareholders’ equity10.5Fiscal year 2023Cash6.7Shareholders’ equity6.6Fiscal year 2024Cash5.7Shareholders’ equity5.5
FY2019FY2020FY2021FY2022FY2023FY2024
Cash 0.1 0.8 19.8 11.6 6.7 5.7
Shareholders’ equity 0.0 0.7 19.4 10.5 6.6 5.5

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2024 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending September, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2019 30 Sep 2019 FY2020 30 Sep 2020 FY2021 30 Sep 2021 FY2022 30 Sep 2022 FY2023 30 Sep 2023 FY2024 30 Sep 2024
Operations
n/a −0.3 −7.3 −13.6 −7.0 −1.9
Growth
Financing
n/a 1.0 26.1 5.2 2.2 0.8

Capital expenditure, dividends and buybacks are shown as money out, so negative.